GB1056192A - Pharmaceutical compositions containing catalase - Google Patents
Pharmaceutical compositions containing catalaseInfo
- Publication number
- GB1056192A GB1056192A GB97765A GB97765A GB1056192A GB 1056192 A GB1056192 A GB 1056192A GB 97765 A GB97765 A GB 97765A GB 97765 A GB97765 A GB 97765A GB 1056192 A GB1056192 A GB 1056192A
- Authority
- GB
- United Kingdom
- Prior art keywords
- mannitol
- catalase
- hexol
- pharmaceutical compositions
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000016938 Catalase Human genes 0.000 title abstract 6
- 108010053835 Catalase Proteins 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 6
- 229930195725 Mannitol Natural products 0.000 abstract 6
- 239000000594 mannitol Substances 0.000 abstract 6
- 235000010355 mannitol Nutrition 0.000 abstract 6
- 150000004000 hexols Chemical class 0.000 abstract 5
- 239000000243 solution Substances 0.000 abstract 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 abstract 2
- 239000000706 filtrate Substances 0.000 abstract 2
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 abstract 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 abstract 2
- 229960000367 inositol Drugs 0.000 abstract 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 abstract 2
- 239000000600 sorbitol Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 208000000680 lipomatosis Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 239000000829 suppository Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Catalase is stabilized by a hexol, which may be added to it at any stage of its isolation or purification. The hexol may be mannitol, dulcitol, sorbitol, or inositol. In an example, ox liver is comminuted with an aqueous solution of mannitol. The mixture is filtered, catalase being precipitated from the filtrate by the addition of acetone. The crude catalase containing mannitol is dissolved in aqueous mannitol solution, filtered, and the filtrate is dialysed. The catalase precipitate obtained by dialysis is redissolved in buffer solution at pH 7.3 and is allowed to crystallize. The crystals are redissolved in aqueous mannitol solution and lyophilized.ALSO:Pharmaceutical compositions for use in the treatment of arthrosis, hepatitis, lipomatosis, uricaemia, and hypercholestarolaemia contain or consist of catalase stablized by a hexol. The hexol may be derived from a sugar. Specified hexols are mannitol, dulcitol, sorbitol, and inositol. The active substance may be used in the lyophilised form, or with one or more carriers or excipients. The pharmaceutical compositions may be in the form of injectable solutions or suppositories.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR959674A FR1484614A (en) | 1964-01-08 | 1964-01-08 | Catalase stabilization process |
| FR959675A FR3531M (en) | 1964-01-08 | 1964-01-08 | New drug based on catalase. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1056192A true GB1056192A (en) | 1967-01-25 |
Family
ID=26205263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB97765A Expired GB1056192A (en) | 1964-01-08 | 1965-01-08 | Pharmaceutical compositions containing catalase |
Country Status (5)
| Country | Link |
|---|---|
| BE (1) | BE657602A (en) |
| DE (1) | DE1252610B (en) |
| FR (1) | FR1484614A (en) |
| GB (1) | GB1056192A (en) |
| LU (1) | LU47683A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0477143A3 (en) * | 1990-08-30 | 1993-02-24 | Idi Farmaceutici S.P.A. | Pharmaceutical composition having a cicatrising effect |
| EP2648721B1 (en) * | 2011-01-31 | 2018-09-19 | LUCOLAS-M.D. Ltd. | Combinations of aromatase inhibitors and antioxidants |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR8202M (en) * | 1968-10-31 | 1970-09-14 | ||
| DK1417301T3 (en) * | 2001-08-07 | 2007-03-12 | Novozymes As | Carbohydrates and polyols for dissolving protein crystals |
-
0
- DE DENDAT1252610D patent/DE1252610B/en active Pending
-
1964
- 1964-01-08 FR FR959674A patent/FR1484614A/en not_active Expired
- 1964-12-24 BE BE657602D patent/BE657602A/xx unknown
- 1964-12-29 LU LU47683A patent/LU47683A1/xx unknown
-
1965
- 1965-01-08 GB GB97765A patent/GB1056192A/en not_active Expired
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0477143A3 (en) * | 1990-08-30 | 1993-02-24 | Idi Farmaceutici S.P.A. | Pharmaceutical composition having a cicatrising effect |
| EP2648721B1 (en) * | 2011-01-31 | 2018-09-19 | LUCOLAS-M.D. Ltd. | Combinations of aromatase inhibitors and antioxidants |
| US10835540B2 (en) | 2011-01-31 | 2020-11-17 | Lucolas-M.D. Ltd. | Pharmaceutical use |
Also Published As
| Publication number | Publication date |
|---|---|
| FR1484614A (en) | 1967-06-16 |
| DE1252610B (en) | 1967-10-26 |
| LU47683A1 (en) | 1965-03-02 |
| BE657602A (en) | 1965-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1303408A (en) | ||
| GB1056192A (en) | Pharmaceutical compositions containing catalase | |
| BE768724A (en) | PROCESS FOR THE PREPARATION OF CHROME (III) OXIDE LOW IN SULFUR | |
| GB1097102A (en) | Improvements in or relating to combine harvesters | |
| DK316288A (en) | ACARIDID MEDICINE | |
| AT288853B (en) | Process for the treatment of pulp waste liquors by fluidized bed combustion | |
| GB1062434A (en) | Process for isolating -antitrypsin | |
| GB1117769A (en) | Improvements in or relating to combine harvesters | |
| ES353533A1 (en) | Tetanus vaccine and process for preparing it | |
| GB1100443A (en) | 17ª‡-chloroethynyl-13ª‰-ethylgonenolone | |
| GB1272340A (en) | Derivatives of neriifolin | |
| CH471091A (en) | Process for the preparation of N-Benzyl-N ', N' '- dimethylguanidine | |
| GB1271984A (en) | Hydroxylated steroids | |
| USD140349S (en) | Design for a lighter case or similar article | |
| GB845823A (en) | Stabilised compositions comprising therapeutic imine derivatives and the preparation thereof | |
| GB1343586A (en) | Pyridine bis-dithiocarbamate- derivatives and preparation thereof | |
| CH448099A (en) | Process for the preparation of 1-naphthyl-acetic acid esters of N, N'-di- (B-hydroxyethyl) piperazine | |
| AU407297B2 (en) | Concentration of phosphoric acids and concurrent separation of impurities | |
| ES2051831T3 (en) | LABILE KETONIC DERIVATIVES OF 1-ALKYLAMINO-2-PROPANOLS REPLACED IN POSITION 3 AND THEIR USE AS ADRENERGIC BETA-BLOCKERS. | |
| ES373763A1 (en) | Fibrinolysokinases from streptomyces | |
| GB1036283A (en) | A substituted amide | |
| GB1036059A (en) | Improvements in or relating to the inhibition of bacterial growth | |
| GB1210063A (en) | Immunogenic preparations and a process for their production | |
| CH483441A (en) | Process for the preparation of 3-hydroxy-1,2,5-thiadiazole compounds | |
| GB1254948A (en) | Antivirial substance |